代表的業績

1. Takeda M, Ohno S, Tahara M, Takeuchi H, Shirogane Y, Ohmura H, Nakamura T, Yanagi Y. Measles
   viruses possessing the polymerase protein genes of the Edmonston vaccine strain exhibit attenuated gene
   expression and growth in cultured cells and SLAM knock-in mice. J Virol. 2008;82(23):11979-11984.
2. Ohmura H, Uchino K, Kajitani T, Sakamoto N, Baba E. Predictive value of the modified Glasgow Prognostic
   Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. Mol Clin
   Oncol. 2017;6(5):669-675.
3. Inadomi K, Kusaba H, Matsushita Y, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A,
   Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama H,
   Akashi K, Baba E. Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric
   Cancer. Anticancer Res. 2017;37(5):2663-2671.
4. Yamaguchi K, Mishima K, Ohmura H, et al. Activation of central/effector memory T cells and T-helper 1
   polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. Cancer Sci.
   2018;109(10):3032-3042.
5. Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, Yoshihiro T, Ohmura H, Tsuruta N,
   Hanamura F, Sagara K, Okumura Y, Nio K, Tsuchihashi K, Arita S, Kusaba H, Baba. PD-1+ TIM-3+ T cells in
   malignant ascites predict prognosis of gastrointestinal cancer. Cancer Sci. 2018;109(9):2986-2992.
6. Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino
   K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Hisanobu O, Esaki T,
   Akashi K, Baba E. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric
   Cancer. 2018;21(3):464-472.
7.  Tsuruta N, Tsuchihashi K, Ohmura H, et al. RNA N6-methyladenosine demethylase FTO regulates PD-L1
   expression in colon cancer cells. Biochem Biophys Res Commun. 2020;530(1):235-239.
8. Yamaguchi K, Ito M, Ohmura H, et al. Helper T cell-dominant tertiary lymphoid structures are associated
   with disease relapse of advanced colorectal cancer. Oncoimmunology. 2020;9(1):1724763.
9. Ohmura H, Yamaguchi K, Hanamura F, et al. OX40 and LAG3 are associated with better prognosis in
   advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer.
   2020;122(10):1507-1517.
10.  Ohmura H, Ito M, Uchino K, et al. Methylation of drug resistance-related genes in
    chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer. FEBS Open Bio.
    2020;10(1):147-157.
11.  Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K, Shirakawa T, Otsuka T,
    Ohmura H, Isobe T, Ariyama H, Koreishi S, Matsushita Y, Shimokawa H, Tanaka R, Mitsugi K, Akashi K,
    Baba E. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and
    neck squamous cell carcinoma receiving nivolumab. Sci Rep. 2021;11(1):2741.
12. Kusaba H, Moriyama S, Hieda M, Ito M, Ohmura H, Isobe T, Tsuchihasi K, Fukata M, Ariyama H, Baba E.
    IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous
    thromboembolism. Jpn J Clin Oncol. 2022;52(10):1183-1190.
13.  Taguchi R, Tsuchihashi K, Okumura Y, Nakano M, Yoshihiro T, Ohmura H, Tsuruta N,
    Hanamura F, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K, Baba E.
    Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer.
    Intern Med. 2020;59(20):2571-2575.
14. Ueno S, Uenomachi M, Kusaba H, Ito M, Suzuki K, Ohmura H, Tsuchihasi K, Ariyama H,
    Akashi K, Baba E. Improvement in recurring nivolumab-induced pneumonitis with repetitive
    administration of infliximab in a patient with head and neck cancer: A case report. Mol Clin
    Oncol. 2021;15(4):221.
15.  Yamaguchi K, Tsuchihashi K, Tsuji K, Kito Y, Tanoue K, Ohmura H, Ito M, Isobe T,
    Ariyama H, Kusaba H, Akashi K, Baba E. Prominent PD-L1-positive M2 macrophage
    infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report.
    Medicine (Baltimore). 2021;100(19):e25773.
16. Ohmura H, Masuda T, Mimori K, Baba E, Horiuchi T. A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax. Int Cancer Conf J. 2022;12(1):31-35.
17. Tsuchihashi K, Kusaba H, Yoshihiro T, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Imajima T, Shinohara Y, Ito M, Yamaga S, Tanoue K, Arimizu K, Ohmura H, Hanamura F, Yamaguchi K, Isobe T, Ariyama H, Nakashima Y, Akashi K, Baba E. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin. Sci Rep. 2020;10(1):20896.
18. Masuda T, Ueo H, Okumura Y, Kai Y, Ando Y, Masuguchi K, Kitagawa M, Kitagawa A, Hayashi N, Tsuruda Y, Hisamatsu Y, Suehiro S, Ohmura H, Fujiyoshi K, Tanaka F, Mimori K. Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer. Cancer Genomics Proteomics. 2023 Mar-Apr;20(2):182-194.
19. Ohmura H, Tobo T, Mimori K, Baba E, Horiuchi T. Trousseau's Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report. Case Rep Oncol. 2023 Jul 3;16(1):484-490.
20. Uehara K, Tanoue K, Yamaguchi K, Ohmura H, Ito M, Matsushita Y, Tsuchihashi K, Tamura S, Shimokawa H, Isobe T, Shibata Y, Ariyama H, Tanaka R, Kusaba H, Yamamoto H, Oda Y, Akashi K, Baba E. Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions. Cancer Immunol Immunother. 2023 Nov;72(11):3543-3558.
21. Ohmura H, Kondo M, Uenomachi M, Ariyama H, Ito M, Tsuchihashi K, Ayano M, Niiro H, Akashi K, Baba E. Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer. Front Oncol. 2023 Oct 5;13:1260818.